Fluicell (FLUI.ST) Stock Analysis & AI Equity Report

Biotechnology SEK Explore free reports

Fluicell (FLUI.ST) overview

Fluicell (FLUI.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Fluicell reported revenue of SEK 6.0m and operating profit of SEK -8.7m; the year-end share price was 10.00 SEK and market capitalisation was SEK 813m. Fluicell is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Fluicell's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueSEK 10.9mFY 2025
Share price10.00 SEKFY 2025 year end
RevenueSEK 6.0mFY 2025
Operating profitSEK -8.7mFY 2025
Net earningsSEK -8.3mFY 2025
Market capitalisationSEK 813mFY 2025 year end

Figures updated on 2026-07-27. Data will be refreshed during report generation.

About Fluicell

Fluicell develops microfluidic and single-cell technology for life science research and regenerative medicine. Its products include the BioPen, Biozone 6 and Dynaflow Resolve research tools, the Biopixlar bioprinting platform and the Nexocyte tissue production platform. The company also advances tissue-based therapeutics and screening models for applications such as type 1 diabetes, cardiac toxicity and kidney disease.

Generate the Fluicell report

Fluicell is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, typically within about 30 minutes

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Fluicell and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Fluicell

Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.